<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36864896</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1687-9813</ISSN><JournalIssue CitedMedium="Internet"><Volume>2023</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of environmental and public health</Title><ISOAbbreviation>J Environ Public Health</ISOAbbreviation></Journal><ArticleTitle>Effects of DNA Immunoadsorption Combined with Medication on Immune Function and Renal Function in Patients with Systemic Lupus Erythematosus.</ArticleTitle><Pagination><StartPage>2843979</StartPage><MedlinePgn>2843979</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2843979</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2023/2843979</ELocationID><Abstract><AbstractText><i>Objective</i>. At present, glucocorticoids combined with cyclophosphamide are still used for the clinical treatment of systemic lupus erythematosus (SLE). However, long-term practice has shown that drug treatment currently has the phenomena of long treatment duration, uncontrollable conditions in a short period of time, and unsatisfactory efficacy. DNA immunoadsorption therapy is a newly developed therapy. The combination of drugs and DNA immunoadsorption has been reported for the treatment of SLEN in clinics for a long time. In this study, we observed the effects of DNA immunoadsorption combined with drug therapy on immune function and renal function in patients with systemic lupus erythematosus (SLE). The results showed that the DNA immunosorbent assay combined with medication in the treatment of SLE could quickly and specifically remove pathogenic substances from patients, improve renal function, immune function, and complement levels in patients, and help to relieve disease activity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Lijie Bai et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Lijie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Affiliated Hospital of Inner Mongolia Medical University, Huhehaote 010059, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Mingxia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Hohhot First Hospital, Huhehaote 010000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Guiying</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Affiliated Hospital of Inner Mongolia Medical University, Huhehaote 010059, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Affiliated Hospital of Inner Mongolia Medical University, Huhehaote 010059, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Affiliated Hospital of Inner Mongolia Medical University, Huhehaote 010059, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8661-5190</Identifier><AffiliationInfo><Affiliation>Inner Mongolia Medical University, Huhehaote 010059, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Liying</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5131-2678</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Affiliated Hospital of Inner Mongolia Medical University, Huhehaote 010059, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Environ Public Health</MedlineTA><NlmUniqueID>101516361</NlmUniqueID><ISSNLinking>1687-9805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>2</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36864896</ArticleId><ArticleId IdType="pmc">PMC9974245</ArticleId><ArticleId IdType="doi">10.1155/2023/2843979</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiriakidou M., Ching C. L. Systemic lupus erythematosus. Annals of Internal Medicine . 2020;172(11):ITC81&#x2013;ITC96. doi: 10.7326/aitc202006020.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/aitc202006020</ArticleId><ArticleId IdType="pubmed">32479157</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T., Furie R. Novel paradigms in systemic lupus erythematosus. The Lancet . 2019;393(10188):2344&#x2013;2358. doi: 10.1016/S0140-6736(19)30546-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30546-X</ArticleId><ArticleId IdType="pubmed">31180031</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh J. Targeted delivery of immunosuppressant in SLE. Nature Reviews Rheumatology . 2020;16(8):p. 410. doi: 10.1038/s41584-020-0462-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0462-9</ArticleId><ArticleId IdType="pubmed">32612265</ArticleId></ArticleIdList></Reference><Reference><Citation>Stummvoll G., Aringer M., Handisurya A., Derfler K. Immunoadsorption in autoimmune diseases affecting the kidney. Seminars in Nephrology . 2017;37(5):478&#x2013;487. doi: 10.1016/j.semnephrol.2017.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semnephrol.2017.05.020</ArticleId><ArticleId IdType="pubmed">28863794</ArticleId></ArticleIdList></Reference><Reference><Citation>Stummvoll G. H., Aringer M., Smolen J. S., et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Annals of the Rheumatic Diseases . 2005;64(7):1015&#x2013;1021. doi: 10.1136/ard.2004.029660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.029660</ArticleId><ArticleId IdType="pmc">PMC1755551</ArticleId><ArticleId IdType="pubmed">15640267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombardier C., Gladman D. D., Urowitz M. B., et al. Derivation of the sledai. A disease activity index for lupus patients. Arthritis &amp; Rheumatism . 1992;35(6):630&#x2013;640. doi: 10.1002/art.1780350606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780350606</ArticleId><ArticleId IdType="pubmed">1599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivas-Larrauri F., Yamazaki-Nakashimada M. A. Systemic lupus erythematosus: is it one disease? Reumatolog&#xed;a Cl&#xed;nica . 2016;12(5):274&#x2013;281. doi: 10.1016/j.reuma.2016.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2016.01.005</ArticleId><ArticleId IdType="pubmed">26922326</ArticleId></ArticleIdList></Reference><Reference><Citation>Illescas-Montes R., Corona-Castro C. C., Melguizo-Rodr&#xed;guez L., Ruiz C., Costela-Ruiz V. J. Infectious processes and systemic lupus erythematosus. Immunology . 2019;158(3):153&#x2013;160. doi: 10.1111/imm.13103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13103</ArticleId><ArticleId IdType="pmc">PMC6797874</ArticleId><ArticleId IdType="pubmed">31386190</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer B. N., Kamen D. L. Gastrointestinal and hepatic disease in systemic lupus erythematosus. Rheumatic Disease Clinics of North America . 2018;44(1):165&#x2013;175. doi: 10.1016/j.rdc.2017.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2017.09.011</ArticleId><ArticleId IdType="pmc">PMC5796428</ArticleId><ArticleId IdType="pubmed">29149925</ArticleId></ArticleIdList></Reference><Reference><Citation>Basta F., Fasola F., Triantafyllias K., Schwarting A. Systemic lupus erythematosus (SLE) therapy: the old and the new. Rheumatology and Therapy . 2020;7(3):433&#x2013;446. doi: 10.1007/s40744-020-00212-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40744-020-00212-9</ArticleId><ArticleId IdType="pmc">PMC7410873</ArticleId><ArticleId IdType="pubmed">32488652</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M., Johnson S. R. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology . 2020;59(5):v4&#x2013;v11. doi: 10.1093/rheumatology/keaa379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa379</ArticleId><ArticleId IdType="pmc">PMC7719035</ArticleId><ArticleId IdType="pubmed">33280013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko K., Chen H., Kaufman M., Sverdlov I., Stein E. M., Park-Min K. H. Glucocorticoid-induced osteonecrosis in systemic lupus erythematosus patients. Clinical and Translational Medicine . 2021;11(10):p. e526. doi: 10.1002/ctm2.526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.526</ArticleId><ArticleId IdType="pmc">PMC8506634</ArticleId><ArticleId IdType="pubmed">34709753</ArticleId></ArticleIdList></Reference><Reference><Citation>Du T., Pang H., Ding F., et al. Reduction in SLEDAI is associated with improved arterial stiffness in systemic lupus erythematosus. Medicine (Baltimore) . 2020;99(47) doi: 10.1097/MD.0000000000023184.e23184</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023184</ArticleId><ArticleId IdType="pmc">PMC7676556</ArticleId><ArticleId IdType="pubmed">33217825</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C., Carlsson D. O., Mihranyan A. Feasibility of using DNA-immobilizednanocellulose-based immunoadsorbent for systemic lupus erythematosus plasmapheresis. Colloids and Surfaces B: Biointerfaces . 2016;143:1&#x2013;6. doi: 10.1016/j.colsurfb.2016.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2016.03.014</ArticleId><ArticleId IdType="pubmed">27011345</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentow C., Rosenblum R., Correia P., et al. Development and multi-center evaluation of a novel immunoadsorption method for anti-DFS70 antibodies. Lupus . 2016;25(8):897&#x2013;904. doi: 10.1177/0961203316641773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316641773</ArticleId><ArticleId IdType="pubmed">27252267</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Xiao S., Xia Y., Wang H. The therapeutic strategies for SLE by targeting anti-dsDNA antibodies. Clinical Reviews in Allergy and Immunology . 2021;63(2):152&#x2013;165. doi: 10.1007/s12016-021-08898-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-021-08898-7</ArticleId><ArticleId IdType="pmc">PMC9464114</ArticleId><ArticleId IdType="pubmed">34542806</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohenstein B., Bornstein S. R., Aringer M. Immunoadsorption for connective tissue disease. Atherosclerosis Supplements . 2013;14(1):185&#x2013;189. doi: 10.1016/j.atherosclerosissup.2012.10.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosissup.2012.10.034</ArticleId><ArticleId IdType="pubmed">23357163</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L., Lu M. P., Wang J. H., Xu M., Yang S. R. Immunological pathogenesis and treatment of systemic lupus erythematosus. World Journal of Pediatrics . 2020;16(1):19&#x2013;30. doi: 10.1007/s12519-019-00229-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-019-00229-3</ArticleId><ArticleId IdType="pmc">PMC7040062</ArticleId><ArticleId IdType="pubmed">30796732</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrada A. A., Escobedo N., Iruretagoyena M., et al. Innate immune cells&#x2019; contribution to systemic lupus erythematosus. Frontiers in Immunology . 2019;10:p. 772. doi: 10.3389/fimmu.2019.00772.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00772</ArticleId><ArticleId IdType="pmc">PMC6476281</ArticleId><ArticleId IdType="pubmed">31037070</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos G. C. Autoimmunity and organ damage in systemic lupus erythematosus. Nature Immunology . 2020;21(6):605&#x2013;614. doi: 10.1038/s41590-020-0677-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0677-6</ArticleId><ArticleId IdType="pmc">PMC8135909</ArticleId><ArticleId IdType="pubmed">32367037</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein A., Alexander R. V., Zack D. J. A review of complement activation in SLE. Current Rheumatology Reports . 2021;23(3):p. 16. doi: 10.1007/s11926-021-00984-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-00984-1</ArticleId><ArticleId IdType="pmc">PMC7875837</ArticleId><ArticleId IdType="pubmed">33569681</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada T., Fujimori D., Yamamoto Y. Systemic lupus erythematosus and immunodeficiency. Immunological Medicine . 2019;42(1):1&#x2013;9. doi: 10.1080/25785826.2019.1628466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/25785826.2019.1628466</ArticleId><ArticleId IdType="pubmed">31204893</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Tang M., Huang L. L., et al. Ginsenoside 3&#x3b2;-O-Glc-DM (C3DM) enhancesthe antitumor activity of Taxol on Lewis lung cancer by targeting the interleukin-6/Jak2/STAT3 and interleukin-6/AKT signaling pathways. World Journal of Traditional Chinese Medicine . 2020;6(4):432&#x2013;440. doi: 10.4103/wjtcm.wjtcm_51_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/wjtcm.wjtcm_51_20</ArticleId></ArticleIdList></Reference><Reference><Citation>Maria N. I., Davidson A. Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy. Nature Reviews Rheumatology . 2020;16(5):255&#x2013;267. doi: 10.1038/s41584-020-0401-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0401-9</ArticleId><ArticleId IdType="pubmed">32203285</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolios A. G. A., Tsokos G. C. Skin-kidney crosstalk in SLE. Nature Reviews Rheumatology . 2021;17(5):253&#x2013;254. doi: 10.1038/s41584-021-00588-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00588-0</ArticleId><ArticleId IdType="pubmed">33633360</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M. Inflammatory markers in systemic lupus erythematosus. Journal of Autoimmunity . 2020;110 doi: 10.1016/j.jaut.2019.102374.102374</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.102374</ArticleId><ArticleId IdType="pubmed">31812331</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Santos M., Veronese F. V., Moresco R. N. Uric acid and kidney damage in systemic lupus erythematosus. Clinica Chimica Acta . 2020;508:197&#x2013;205. doi: 10.1016/j.cca.2020.05.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.05.034</ArticleId><ArticleId IdType="pubmed">32428504</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun N., Erley C., Klein R., K&#xf6;tter I., Saal J., Risler T. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrology Dialysis Transplantation . 2000;15(9):1367&#x2013;1372. doi: 10.1093/ndt/15.9.1367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/15.9.1367</ArticleId><ArticleId IdType="pubmed">10978392</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M., Liao C., Zhu Q., et al. Meta-analysis on the efficacy and safety of immunoadsorption for systemic lupus erythematosus among Chinese population. Clinical Rheumatology . 2020;39(12):3581&#x2013;3592. doi: 10.1007/s10067-020-05156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05156-7</ArticleId><ArticleId IdType="pubmed">32468321</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronbichler A., Brezina B., Quintana L. F., Jayne D. R. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmunity Reviews . 2016;15(1):38&#x2013;49. doi: 10.1016/j.autrev.2015.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.08.010</ArticleId><ArticleId IdType="pubmed">26318215</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Song G., Yin Z., et al. Rapid reduction of antibodies and improvement of disease activity by immunoadsorption in Chinese patients with severe systemic lupus erythematosus. Clinical Rheumatology . 2016;35(9):2211&#x2013;2218. doi: 10.1007/s10067-016-3354-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-016-3354-2</ArticleId><ArticleId IdType="pubmed">27488202</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>